“I am moving on. Can we discuss the upcoming interim look at CD12? I think it is very exciting that that data is being compiled as we speak.”

Please let option 4, per NP’s description, be the outcome. The EIND patients are a good hint at what leronlimab can do in the S/C population and I hope the results are being reproduced.